Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non-small cell lung carcinoma.
Nobuyuki HiramaMasaki YamamotoSatoshi NagaokaWataru SegawaChihiro SugimotoHirokazu NagayamaShuntaro HiroYukihito KajitaChihiro MaedaSousuke KuboKenichi SekiYoshinori NagaharaShuhei TeranishiKen TashiroYu HaraNobuaki KobayashShigenobu WatanabeMakoto KudoTakeshi KanekoPublished in: Thoracic cancer (2023)
RLPV20 and RLPV5 are useful in estimating lung inflammation. RLPV20 could be considered the most reliable risk factor for maintenance therapy with durvalumab following concurrent chemoradiotherapy in patients with unresectable locally advanced NSCLC.
Keyphrases